HUMA - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. And welcome to the Humacyte Second Quarter 2022 Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time.

As a reminder, this conference call is being recorded. the to turn LifeSci Marek now Advisors. will call Lauren over with I go Please ahead.

Lauren Marek

Operator. you, Thank

statements The the presented proceed call could forward-looking we obligation the remind SEC. made are risks hereof to of the laws. certain to call, subject and today are everyone forward-looking statements federal and the to forward-looking only These call accessed date page statements this call uncertainties Before during Information we the our that with that Humacyte I revise contained or statements and with release U.S. website. is in and securities under Investors statements this would issued results except Any concerning made this the maybe factors filed no call update XX-Q, morning that cause actual from speak in materially on as information during differ contained the required from historical is experience which made be cause undertakes reports additional of actual to Form in periodic press from results the to company or differ law. statements present filed as will expectations. our by could this this like on

Operating review progress President the call and the Dr. are of from weeks Chief Joining quarter Chief me on Niklason will today’s Executive summary Dr. and Laura will the results. a company’s Officer; Officer Chief Officer. company’s Humacyte Dr. and Corporate Prichard, and Dale Heather Niklason, and Chief provide Financial Sander, Dale during recent financial Development Officer;

turn will Dr. for the your Following to be I will over call remarks, available their prepared Niklason. the now management team questions.

Dr. Laura Niklason

XXXX call. thank morning, everyone, you second for joining business update you, and our results for Thank Good financial us and Lauren. quarter

progress financial programs, I’m the platform. Humacyte this turning second our call the your I’ll a universally be pleased the quarter to up has happy before key progress recent our review our very in our tissue for Dale great throughout to of Then and results. the we for During human over highlights of call advancing with will call, questions. open made bioengineered implantable review

the collaboration and humanitarian well add the body robust or that invaluable initiative as Ministry International drug strengthened Diane of to global inadequate. our initiative the of complex and of vascular for the provide We’ve vascular on which Administration, launched Parikh, also trauma or be of continuing We Board of Shamik and export respective move Office of Drug will HAV, that with uniquely Dr. with goal We’re organ team, HAV. our U.S. data as market. treatment is our the update Programs Directors experience of leadership with civilians to the to bringing for in suffering as Dr. suited Ukraine appointments the HAV multiple to in coordinate hospitals may in lead vessels both our be an who to within injuries. closer acellular applications, either and and begin to wounded showing this HAVs standard-of-care human Health from investigational the May current unavailable our we Seimetz, Ukraine I’ll import Food bring in the candidates, of to the development

potential evidence of wartime salvaging further the real injured limbs and impact is this in HAV This to have We’re free, infection been patients zone. very injuries. trauma trauma proud to who with in all reported been Ukrainian To-date, report have the into world injuries. of the be vascular of been that patients and implanted functional HAVs successfully that implanted program humanitarian treatment are vascular providing have several HAVs conflict

the ongoing medical hospitals by that humanitarian help to patients are and and efforts to honored relief to Ukraine affected We’re contribute frontline the crisis. in

on teams in the work In the limbs addition, patients medical will treated the Ukraine we’re the of to were with are HAV, continue ground, the quickly of an in effort of in and save patients with save trained and use help FDA HAV lives as on who the Ministry inspired Ukrainian Health to the by dedicated with need.

late-stage the progress. Phase trauma, our to HAV on program Moving vascular is trial for continuing clinical in X/X to our

As a of and settings. for is reminder, this open a total we’ve trauma a repair, single evaluating XX injury non-randomized arm study, vascular Currently, reconstruction in enrolled trial HAVs label patients. replacement

less of high very low HAV BLA amputations We’re planned HAV limb with X%. end reports from study FDA, are the expected as had the a of have to which we’ve by and pleased infection result of submit XXXX malfunction than conduit. also We’ve rates to rates results showing of that observed to-date, of XXXX. no Results early of plan filing with the our trial or the patency the support occurred we

favorable Surgery, emphasize potential A journal subject HAV The discuss of second potential and X,XXX also and from years number clinical and the the In indicated perspectives, We’re in to a clinical of XXXX FDA AV the nearly enlightening patients Researchers patients. manuscript for the HAVs presentations or of trial of June patients insightful for multiple trauma website. results Drs. care of found completion access qualifies track Ernest up. of dialysis of XXX in conferences opinion of also trials, on This turn a Dr. I’d XXXX, featuring indication be enrolled Moore anticipated to potential was impact completed BLA the Moore be HAV standard-of-care development was XXX scientific approval of the The this the HAV trial The filing built successful, a X for researchers will one-year HAV up assess limitations over continuing pathway. subjects of year, the publication fistulas is the the the end multiple the to the discussion Phase the in indication. comparison trauma. topline designed the hemodialysis period capacity trauma nearing follow into late and HAVs stage The to HAV highlighted the based Magee upon to Humacyte advantages from at make data quarter. to was described Events their are highlighted existing publications we of leaders, has the to follow previously significant in webinar of on vascular arteriovenous and currently in Dr. the patient our we which study. throughout the if and for promised in for edition disease over program encompassing required vascular the to that This in is in support be clinical Results the JAMA the further both with access accelerated with dialysis XXX we’re trial, usability of page grateful patients for With July, enrolled, key in webinar and up HAV to for that’s presentations. to replay like the with an FDA. vascular that on approaches. for renal with to autogenous can the now hosted our disease. address current enrollment of vascular Magee. the in of a Enrollment patients Greg

X on panel than not Humacyte American stimulate immune HAV presented that’s correlated In clinical patient is from demonstrating Congress, increase data in years which reactive addition, XXX does with June an the in Transplant response tissue trials, more an at and exposure Phase of antibodies, the that Phase adaptive rejection. X

instances graft across a [ePFTE] received antibodies, HAV either to polytetrafluoroethylene graft. These increases the or who in or are of (sic) access. HAV the sensitization women of of addition, appeared patients stage of demonstrated AV be the PTFE the In compared renal Phase PTFE results the X synthetic HAV women, with HAV. implanted to who performed consistent The as who The greater with further PTFE the HAV exhibited the benefit patients rejection than trials that in graft. end fewer been been even trial that’s disease have patients who received with received absence fewer observed for in

partner value-based strengthen Care, shareholder, with progress this in we’re which kidney and toward we and care. care leader the Medical to Fresenius is in products As continuing relationship our global commercialization our services, global indication,

evaluate of patency owned Scientific in integrity to a Sciences the of These for Cardiovascular In structural maintained with for patients both research evidence repopulation. partnering robust a and model, post-implantation cell care Association, the Basic cost primate vulnerable HAV, We’re hemodialysis Fresenius up is the or Europe. in access and group and remodeling HAV Frenova, non-human clinical U.S. which and complications the by in will development small-diameter of with and to host artery bypass with were positive we CABG study programs, In the from assist preclinical kidney HAV economic stage results In our of HAVs earlier evaluations studies July, patients failure. health our at Heart advance the coronary American of models grafting preclinical value in propositions to for presented CABG. and six particularly months Sessions. showed continuing

We’re September a Circulation and excited promise issue our of small-diameter to study in CABG look continue that models show we in preclinical of to publication HAVs this Research. forward

Executive to of has XXXX. international Seimetz welcome she of In Seimetz, team development, in appointments Excellence, June, our Officer development. global acquisition its industry. serving managerial co-founded over partnering In leadership biopharmaceutical with in experience and Biopharma Humacyte the in we XXXX, clinical Chief Finally, Dr. Ph.D Board strengthened of Directors years quarter, its the Diane drug XX of brings our and as until experts this Board Directors. seasoned

preclinical Medical global and affairs In of operations Parikh strategy, the addition, leads our last Shamik Chief clinical including function. Dr. Parikh, medical welcome as M.D. announced clinical development as new Officer. development, quarter, we oversight the clinical our and

it and adding the and to We’re over that, turn have forward pleased financial so results other and now expertise look and I’ll to With to review join business our of team. Parikh Humacyte Dale insights to we Drs. us a developments. their for Seimetz

Dale Sander

Thank you, Laura.

June of Research HAV. six second of quarter in the We to XX, XX quarter XXXX, was XXXX, million to the second to XXXX, XXXX preparation being launch. increases of of net for company. the the December equivalents ended in XXXX. of to expenses short-term June the research related in of June months ended compared second net initiatives Laura for clinical the expected XX, resulted first current investments six compared $X.X to XXXX, for $XX.X the XX. non-cash loss and XXXX. cash of million ended June million XXXX, year June increases the believe six million quarter $XX.X six operations the and for to of compared commercial remeasurement grants for XXXX, XX, XXXX, resulted The million of XX, expenses the to income periods XX, the for for company the incurred other increase for compared quarter June The from the was to were prior a for team million including $X.X our decrease of for professional With second $XX.X and and and million second second months Corp. use the million commercial compared June and million U.S. concluding million the the preparation Revenue months six $XX.X XXXX, of equivalents costs. turn quarter, income XX, development the increases with gains public from XXXX, and June net $XX.X approval supporting HAV the months stock current ended as the for quarter in to the $XX.X related anticipated earn-out and compared restructuring transition $XX.X for period, reported also for quarter equivalents million by personnel primarily the to a XXXX, remarks. for trauma. $X.X compared costs, ended XXXX. from million, months cash, expense launch were and anticipated General to prior support months a June August for ended XX, related associated for June the all the to expenses current months $XX.X operating from the cash months XX, XXXX, the management to the merger of resulted As resulted short-term $XX of million accommodate primarily of $X.X public $XXX.X $XX.X and being compared $X.X six for of quarter of of are fund XXXX XX, increased for was the programs, net stage income cash, to XXXX. second months million development cash, development were The quarter the XXXX the six $XX.X increases million liability period quarter million income to was were compared six XX, $XX our a clinical June income other XXXX adequate ended expanded and in period, of described Other through for of as XX, compensation in short-term Healthcare net transition the The timelines ended for $X.X back resulted income six for for that, the trials. offset cash in for described in ended net to million including year Acquisition the six that Revenue and net related was XX, to XXXX research already, to XXXX of compared second the XXXX, of The above. we million during ended $XX.X with the and partially personnel fees XXXX, $X.X anticipated the million resulted compared period primarily XXXX, second loss months quarter XX, and months The for of Alpha activities six current vascular net to over from to spending compared for HAV, support our XX, Net development net investments from non-cash contingent compared the administrative earlier million increased second and to expense of period $XXX was $X.X primarily million million June into XXXX I’ll XXXX. six investments months to insurance in increases for the million XXXX June to it quarter the

Dr. Laura Niklason

indications you, we’ve made in half To that across the Thank conclude, the progress first Dale. multiple year. we’re pleased of with the

move milestones exciting runway latter Operator, and anticipated an believe we in through value Humacyte, ready we’re an to to inflection the clinical into and beyond. with regulatory As on we’re questions. months. of the points we’re deliver We half entering well-positioned XXXX, for time carry to us take significant cash coming

Operator

Thank your Street Our question you. Capital. O'Neil from line with Lake comes [Operator Please proceed the with Instructions] first of question. Brooks

Brooks O'Neil

picture have and big morning. a good of you Thank I couple questions.

going So about number these Laura, have after the markets, significant potential you markets you of first of which think one most unmet is, big obviously, excited most Can you’re tell needs. a clinical offers Humacyte all just us the and of which are long-term? one

Dr. Laura Niklason

you, being the which Brooks. a It’s would your an interesting children love I say bit you a that… -- little question. asked That’s Thank of like that’s best?

Brooks O'Neil

Right.

Dr. Laura Niklason

in the has … indication short-term, I obviously, just the think for the is appeal company. huge trauma

that terrible I and can the be excellent -- our saying Magee it July, its where was we’ve reinforcing civilian And that. KOL been I about product that we utility the into trained have just can so think our we illustrates and good field go think, and circumstances trauma, in such with out the just fact everything and into outcomes where in just just I that Ukraine success Dr. be efforts they fact was had about had along. spoke this and all product can in that the Dr. humanitarian surgeons meeting thought of Moore validates

And a the about Dialysis will to which particularly focused from lot years. And anticipate really vascular dialysis we that Level we research I’m on study excited research our both the the is a most now. that -- part Europe. our Fresenius anticipate range clinical to of -- doing again, obviously, I the results patients the trauma of of of studies of trauma trauma the being centers product and Frenova this surgeons, on going been as the us hands is understand that, use of that’s help experienced the see we’re the broad data applications. number Frenova in with are with expect something market right and also first. from to benefit when X a U.S. because in for we’ve in it in So, that and collaboration

worth at We’re hundreds patients’ data. looking of of thousands of

tremendous opportunity will patients best benefit. who hone a on for to it’s those So us really in

Brooks O'Neil

all I your few having a tremendously Great. just you’ve and people have your accomplished excited weeks with visited I and say, of indications. facilities to, and mean, you’re really it’s all all that talk about ago. I’m doing, these impressive

that and lot a lot SPAC Obviously, come people more I you most great. free pressure it’s suited ill of One was think comment. time have to to that comment the that a maybe I advised I please under question mergers Dale, get either of but in marketplace. feel an So think of

I a as comment feel future. you For you what having well today can But you SPAC the company? you just that’s for and a think, guys, on it’s how about positioned you for done extremely in participated merger

Dale Sander

mean, Brooks, lot public the take to in provided was in a well in that which past also to of trauma which in anticipated us timeline Yeah. and be here important we merger we launch, for be first United a the States. I our company, us evolution took transition the transaction SPAC certainly, expect resources vascular think approval our

was to as as more milestones, company in the just we don’t served our public. in time, that public And guess, improve four I’ve as did me, a well. worked in that IPOs SPAC than the newly us shareholders for relatively over a hit has shareholders and transaction in think And feel value any had that directly a be I and will multiple mean, I has is, gone rewarded I that the Europe. like any other been I our expectation companies. than XX So for prior biotech we as U.S. resources than our during an it expect as and on IPO years shareholders I one my company industry the different given this company,

Brooks O'Neil

Absolutely make sense congratulations on much all and to me. the progress. Thank you very

Dale Sander

Thank you.

Operator

with line Our comes proceed next from Please question. question with Zimmerman of BTIG. Ryan the your

Ryan Zimmerman

door to taking I’m Laura, just morning. I VXXX, visit, some not to trial? VXXX mistaken, the trial, think, the some Thanks of those the status my Israel, to newish, be and questions. for the enrollment in the process patients guess, the say. Good in I should enrollment are get you least for new What’s think, I if for at starting to I wanted about those trauma and able sites site talking start were at you’re see,

Dr. Laura Niklason

Yes.

U.S. we’re So one law or anticipating in sites it domestic bit conflict under know. very process some those a the Israel, also activating soon. looking Israeli than with four of at we we’re sites sites in been the two fully a the other is activated as Israel obviously consenting have is And is active different site and little

So Israeli it’s while that wish of that, expecting that we anyone contributions by hoping are we course, are, we’re sites now. never still something activating and be injury, will substantial. But enrollment right would we the

Ryan Zimmerman

And the in know are HAV Okay. you VXXX answer there’s as but the getting that of trial, of no the utilize think, question, this the Fair then, of any enough. is enrollment patients I imagine, I correct? to Ukrainian part potential

Dr. Laura Niklason

mean, this So a that’s humanitarian I correct. is effort.

a in a doing clinical not trial with war zone patients in certainly need. We’re

indication would effort. certainly is of regulators, very the of data whether provided in any it’s real on or world I trauma That include do Europe information make said, the to humanitarian that U.S. in So summary to clear. this outcomes the want that

other think information our So VXXX glean But case will study hand the indication. are on to I for patients. the that the able not we’re on these trauma bolster overall hand, the one

Ryan Zimmerman

for about out that. relative operating just And call Thanks, hop Yeah. queue. were at the taking call example, the down little out year? Makes back to I’ll amount to we quarter, if this questions. specific I lower balance think the came last costs, R&D Dale, the for Yeah. in CapEx ending us bit with agree sense. lastly, a of and than look expenses a to, Laura, And how if is perfect in see, expecting Thanks, for Dale. me, completely wanted there’s I any there, to for just quarter. healthy

Dale Sander

Yeah. on comment Ryan, can certainly that.

clinical and So implants we the in and have a many on some trial, enrolled expected so as when we with you financial right the think R&D be given AV have are or we projections is expenses [inaudible] the versus wind trial lifecycles for actually parameters public, expectations. other in how completed and looking seeing ebb though the our -- depending haven’t there. even seen access, both about now. over expenses But or through to line expenses ranges within company, quickly, patients are newly of are any bulk flow VXXX the enrollment their set as are patients cost of down the you

if we’ve to you six to year, close be first end. to the where through that, to it’s of for Beyond were months the probably remainder forward the done what extrapolate going we expected

Ryan Zimmerman

Okay. that. you. Appreciate Thank

Operator

And line with question Matthew of Sandler. the with Piper comes your questions. our Please O'Brien next proceed from

Matthew O'Brien

morning. my Thanks questions. Good taking for

looks like I probably us today. enrollment, the information on in giving the it and you’re study. slow been fairly Laura, fistulas that has The trauma assuming latest the of enrollment from May is both Just as until

So enrollment those want studies? patient far on as make is two goes everything track with to sure as

Dr. Laura Niklason

Yeah.

some I say, we’re slowed We saw of we’re results Again, coming XXX acute respect trauma -- up the we of on XXXX, pick it late it a hoping shall trauma in the trial, down flow end up continuous months. substantially not because anticipate or away. in we trial a the we spring the on in year anticipate there’s you’re certainly topline two, will by is every and the but we With have enrollment to more, of that last or pick little -- do right, to patients mean the patients. herky-jerky, near the enrollment that the enrolling -- are in because reliable study, handful fistula the we endpoint dialysis very month these have in be that would that patients number at like study a So then bit door, are come trauma would a because some is it’s month. how and year the the

We’re things, sites the on and additional brought trial the Mayo as brought to but support us, clinical Clinic mentioned, not to a support, really trials monitors companies, -- impacting on been because we’re are clinical clinical for the we’re sites, bringing heard as with and centers just certainly and these that’s Israeli which so we’re who is actively is nursing doing a working I’ve of to that the on for nursing we’ve site lot an trying on shortage, we’ve about really all limitation trial their working we’ve support the trials also the support ability of trials. some -- staff for also

So we’re out everything can. we pulling

I late track a year. are Certainly, they’re from perhaps, the we’ve this think perhaps FDA file we’re early BLA, had expecting to different. that still the no indication on any numbers year, next that that

total XX patients I’m past. we’ve enunciated -- around the in or XX as still expecting We’re

Matthew O'Brien

have be But XX, that the Laura, full when going XX, can you minus? you’ll Okay. to up XX or that? And on be to clarity to you’ll to exact point, if do sense it’s going it to you going be think any plus be I mean, do know XX, when think know for I number,

Dr. Laura Niklason

very with We have to FDA work the closely. continued

timing on exact not have shared have we’re going to an when number. exact We

that, is still and it. we’ll believe share have information, afraid I that when I’m we’re provide can I all tracking at time. can’t So more say we But I this

Matthew O'Brien

you. Got it. Thank

Operator

line from question. of Please Kalia question next Suraj your the with comes proceed Our Oppenheimer. with

Suraj Kalia

morning, hear Good Can all right? Dale. you me Laura,

Dr. Laura Niklason

Yeah.

Suraj Kalia

Perfect. Hey.

maybe wanted comes have online, say, been specifically Israel just for for been The some follow-up Matt’s But FDA comes Mayo forgive with the VXXX. belaboring patients, ongoing question, of -- going me the XX for on time? what with time, Laura, So, nature FDA some XX discussions to discussions right. the have let’s fine. on that additional XX, online, the is

Dr. Laura Niklason

the given share patients, as also total this setting, think I injury and FDA possible data, it’s arm Well, single understanding population how about an but far should randomize. how that the been can this in about is physically patients, what trial Suraj, not trauma really it’s to in as acute many where a

consent, grafting. we specify as enrolled saphenous this they so, other provide also suitable be for in And must such trial, but who are must options, vein patients not that

a injured effect that suitable, providing are So significant has by definition, morbidity. because patients and patient who these an in other that not is facing acutely are need, if amputation then very population saphenous if of is or much they’re vein

really a regulate filled it’s with I biologics. thinking even a how smart frankly, They partner great of Biologics as CIBER coming are that is trial. the with regulated That’s discussing thinking have essentially we’re biologic, clinical And involve But discussion. injured clinical lot is and they’re, and and the So really regulated the a required that what here. [ph] device been active interpret people, about typically comparator. though a And outstanding for to who as that being though proteins about population frankly, technology. a with antibodies just out about no of device, gene trial involves a data see us Center typically editing in acutely trials an

are to us. obvious think benefits it’s -- I product the but regulators, it’s it’s been a will they process, the be obvious taken time. the that think to of And just I

Suraj Kalia

can Got in you your six-month give on it. Laura, feasibility? some the of us or pilot for the additional CABG the junction anastomotic color status primate

Dr. Laura Niklason

I not and aware, a and -- believe onto coronary bit in X which sewing so adult pounds are and millimeter will that an XX fine CABG absolute are you January it’s in anastomosis sense. studies. large in diameter say a in sized little a their may patient. July are in reported we we’ve are primate, pediatric you primate it’s is be I in as also studying Suraj, weigh as what human large a general -- vessels, like the These it So our adult vessel millimeters are primate diameter is that like about in but about animals human arteries an in X.X

in of technical comes aside It’s to a sewing technical study. territory. so the there vessel millimeter surprising primate compared compared But type vessel, challenges with seen of challenges seen seen with experiments in from doing we And anything X clinical response work. in just what about unique a millimeter we’ve what or earlier this to to the anastomotic trials or we’ve haven’t are these X.X the our

Suraj Kalia

expectations Dale, reason a somewhat? final there’s terms I quarters. A prior in And the runway your is, question, it. in shift subtle your cash the cash Got been changed of for runway ask from language, have

additional Thank questions. would clarity my be appreciated? any taking for Just or color you

Dale Sander

Yeah.

-- going overall guess, our I the thoughts that think, will the terms the always end takes and the today. launching we through the of Suraj, from of proceeds of back case you net in terms still to runway, that’s transaction XXXX our I transaction in had us expected can without original the of healthcare, cash

anticipated of modified past think, in our some value us current certainly, how takes the first can currently and on mindful our But priority beyond the extend that we that current maybe pass terms think there us state the of expected takes we’re expectations even we not launch. timeframe far and the and hand of out cash ensuring so we with inflection of I market medium efforts deferring about modulating point. the about and ways to points the projects approval our balance on that or of approval have on that market cash cash the

Suraj Kalia

Thank you.

Operator

the Cowen. Please Our from your with line proceed with Jennings Josh question. comes next question of

Josh Jennings

how and and on questions. inform of to follow HAV get access stage Frenova inform how just just you as in for for Thanks agreement remind the us the dialysis to want pricing I indication? the And just Fresenius better Hi. understand well? will then will the commercial once this this also Good the collaboration there investigation taking morning. up

Dr. Laura Niklason

try I’ll indications those a well. the multi-part That’s of disease, access as jump and I you’ll of that recall, indications, Fresenius to which that for -- right agreement distribution arterial Josh. Dale some may handle have can question. marketing in But dialysis peripheral what rights as the in Thanks, and would include stipulates the early and Fresenius trauma, Europe. for

U.S., indications site the those same in products distribution in those shoulder indications. For and those marketing Humacyte of the will

patency and dialysis months fistulas on for the many two. example, that’s their problems and on project then going period and readout repeated a to several excited what we infection, of come collecting as repeated us it far in long data types Frenova, several I’m to because month hard about that a in As patients catheter will their on give tend tend terms of patients data the how types in terms or granular time. of on stuck the next of, project, expect these for have XXX,XXX loss, is with we’re in this of of terms with been this to access patients what really mature a are not patients for

geographies, those those the So terms that HAV both in And not on that in then treating difficulties that currently U.S. those will we Europe. understand most have of and focus the undertake these patients There’s will Europe, in pricing access bear we’re are the which treated us allow part market what inform expect patients estimates terms to U.S. really different the have second by really a subsequent identifying costs and work in commercialization. and difficulties the -- existing these patients subsets project, in going the to this would tend to chronic to once their therapies. cost and patients with would I marketing will difficulties, who of in put acceptably to of we which

Josh Jennings

Great. visit just headquarter follow-up our facility that. tour. Thanks from a and And for

of and think hypothesis in have Thanks questions. for understand? intimal hyperplasia taking any an you think during up I single discussion, better mean, HAV, of great that, action how HAV a you little I seen haven’t was follow be I little intimal would just in wanted do mechanism of just the why you hyperplasia our hadn’t been you to-date. mentioned and implanted to ask, experienced to strong maybe

Dr. Laura Niklason

so Josh, some my that to part a that. Yeah. on and a speculation will I little is admit -- scientific bit that of

peripheral it tissue where patients. I we our all that with types anastomotic population, getting discussed is I It’s not those extraordinary times to what most arterial would and grafts. what seen have as little across some in which would which I seen would a are particularly We this This we growth with we in that, and biological these stuck have in some of week, to-date We’ve anastomosis. and our growth, discussed, intimal their though, guess the visit, site we to of a stenosis. the Panis just to is not of you As There’s have population walking phenomenon. with bit evidence Ph.D has grafting. any in because seen length have seen and that patients That’s graft I biopsies signal. a about is three that is we But standard disease of needles of I contributed that of our say, qualify the the a vessel isn’t and don’t dialysis. in nothing dialysis is a essentially vascular certainly, the at the of around say hyperplasia patients of have cleaner we in seen patients. as confirm statement. don’t that that, again, in convincing call

it’s the couple think, to that really we fully of haven’t yet. scientific going I a on a and it that complete conjecture but to belief documented is statement, statement nail it I my a -- down really accuracy frankly, so, years made we And -- take part, us that

Josh Jennings

you. and it. Understood. Thanks clarifying for appreciate Thank No.

Operator

comes Our next Instructions] Please of Jackson with The Bruce Company. [Operator proceed line question. with the question Benchmark your from

Bruce Jackson

and morning progress. congratulations of all Good the Hi. on

months? back to next few So anything to Laura forward pancreas the getting to biovascular children, over your with project, the favorite look

Dr. Laura Niklason

product. to the said stem biovascular partnered we pancreas islets and that look Well, stem from at smaller would have some produce to so parcel companies our as cell earlier, be with we ability of cells part

So progress are there. making we

plans large our for that next are in in animals toward will in doing progress any studies have months. proof-of-principle making efforts say islet the presentations several differentiation late scientific But also initial We we’re year. and we no progressing this I by

still So remain we for on track that.

I’m information. would saying track on share biovascular be than to year. to because that more still compared that, share -- I the pancreas we any want is earlier the definitive a But in been I it’s say to the hesitant when So everything that we’ve

Bruce Jackson

And little be going the trial expense. similar be to Dale, of was question to it the seasonality just a lumpy Great. going last that Is clinical then for, and is research year a year, this pattern bit a because in activity? there or of development Okay.

Dale Sander

ebb is, and flow Bruce, there part trials. R&D clinical of of the of meaningful expenses. Part it are to it’s other components just

dependent scientific an As terms the preparation of a of biologics component as company, But the technology in get also facilities actual for development don’t enhancements ongoing press doing bioprocessing clinical just, doing support that site platform product to we’re the either facility anticipated cost releases key a that visibility manufacturing as through that are and or depend runs certain our maybe of often are in on launch ebb our there associated of cycles also so or tour when bioprocessing we’re drives presentations. and also. cost when the new costs and is additive development really and other the activities on flow see with side experimentation you on to production whatever

Bruce Jackson

Thank you. for right. All me. it That’s

Operator

call. This I’m Humacyte conference quarter thank the second for concludes time. questions participating. in further at this Thank no you, And showing the results queue you

Humacyte (HUMA) 12 Aug 222022 Q2 Earnings call transcript